Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis

Cutis

Volumn 70, Issue 6, 2002, Pages 335-339

  Jorizzo, Joseph ^a   Stewart, Daniel ^b   Bucko, Alicia ^c   Davis, Steven A ^d   Espy, Paul ^e   Hino, Peter ^f   Rodriguez, David ^g   Savin, Ronald ^h   Stough, Dow ⁱ   Furst, Katharine ^j   Connolly, Margaret ^k   Levy, Sharon ^j  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Midwest Cutaneous Research   (United States)

^c Academic Dermatology Associates   (United States)

^d Dermatology Clinical Research Center of San Antonio   (United States)

^e Espy Research Group   (United States)

^f Dermatology Center of Dallas   (United States)

^g International Dermatology Research   (United States)

^h Savin Dermatology Center   (United States)

ⁱ Stough Clinic   (United States)

^j Dermik Laboratories   (United States)

^k Shellstat Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; FLUOROURACIL; MICROSPHERE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; KERATOSIS; MALE; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; FEMALE; FLUOROURACIL; HUMANS; KERATOSIS; LEAST-SQUARES ANALYSIS; MALE; MICROSPHERES; TREATMENT OUTCOME;

EID: 0036885624     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Skin cancer (PDQ) treatment - health professionals. National Cancer Institute Web site. Available at: http://www.cancernet.nci.nih.gov. Accessed September 19, 2000.
2. Cohn BA. From sunlight to actinic keratosis to squamous cell carcinoma. J Am Acad Dermatol. 2000;42(suppl 1, pt 1):143-144.
3. Breza T, Taylor R, Eaglstein WH. Noninflammatory destruction of actinic keratoses by fluorouracil. Arch Dermatol. 1976;112:1256-1258.
4. Dillaha CJ, Jansen GT, Honeycutt WM, et al. Selective cytotoxic effect of topical 5-fluorouracil. Arch Dermatol. 1963;88:247-256.
5. Hodge SJ, Schrodt GR, Owen LG. Effect of topical 5-fluorouracil treatment on actinic keratosis: a light and electron microscopic study. J Cutan Pathol. 1974;1:238-248.
6. Microsponge Systems Information. Enhanced Derm Technologies, Inc. Available at: http://www.pimpleportal.com. Accessed May 16, 2000.
7. Marks R. Epidemiology of non-melanoma skin cancer and solar keratoses in Australia: a tale of self-immolation in Elysian fields. Australas J Dermatol. 1997;38:26-29.
8. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med. 1993;329:1137-1151.
9. Marks R, Foley P, Goodman G, et al. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol. 1986;115:649-655.
10. Wolf JE, Taylor JR, Tschen E, et al. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40:709-711.
11. Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol. 2002;146:94-100.
12. Levy S, Furst K, Chern W. A pharmacokinetic evaluation of 0.5% or 5% fluorouracil topical cream in patients with actinic keratosis. Clin Ther. 2001;23:908-920.
13. Levy S, Furst K, Chern W. Comparison of the skin permeation of three topical 0.5% fluorouracil formulations with that of a 5% formulations. Clin Ther. 2001;23:901-907.